These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 17407159

  • 1. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W.
    Cancer; 2007 May 15; 109(10):1933-9. PubMed ID: 17407159
    [Abstract] [Full Text] [Related]

  • 2. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A.
    Cancer; 2006 Nov 15; 107(10):2337-45. PubMed ID: 17048231
    [Abstract] [Full Text] [Related]

  • 3. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W.
    J Clin Oncol; 2008 Jun 01; 26(16):2653-8. PubMed ID: 18443351
    [Abstract] [Full Text] [Related]

  • 4. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A.
    Cancer; 1996 Jul 15; 78(2):267-72. PubMed ID: 8674002
    [Abstract] [Full Text] [Related]

  • 5. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.
    Breast Cancer Res Treat; 2004 Jul 15; 86(1):9-18. PubMed ID: 15218357
    [Abstract] [Full Text] [Related]

  • 6. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W.
    Cancer; 2005 Jul 15; 104(2):257-63. PubMed ID: 15952182
    [Abstract] [Full Text] [Related]

  • 7. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H.
    Oncol Rep; 2004 Jun 15; 11(6):1331-6. PubMed ID: 15138574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
    Ivanović V, Demajo M, Krtolica K, Krajnović M, Konstantinović M, Baltić V, Prtenjak G, Stojiljković B, Breberina M, Nesković-Konstantinović Z, Nikolić-Vukosavljević D, Dimitrijević B.
    Clin Chim Acta; 2006 Sep 01; 371(1-2):191-3. PubMed ID: 16650397
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T, Santala M.
    Anticancer Res; 2008 Sep 01; 28(5A):2715-9. PubMed ID: 19035300
    [Abstract] [Full Text] [Related]

  • 16. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, Sweep CG.
    J Pathol; 2004 Apr 01; 202(4):395-402. PubMed ID: 15095266
    [Abstract] [Full Text] [Related]

  • 17. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S.
    Clin Cancer Res; 2005 Jul 15; 11(14):5158-66. PubMed ID: 16033831
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
    Sørensen NM, Schrohl AS, Jensen V, Christensen IJ, Nielsen HJ, Brünner N.
    Scand J Gastroenterol; 2008 Jul 15; 43(2):186-91. PubMed ID: 18224564
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.